• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer.激素受体阳性、HER2 阴性早期乳腺癌中 BCT 评分与预后因素的临床验证。
In Vivo. 2019 Nov-Dec;33(6):2133-2139. doi: 10.21873/invivo.11714.
2
Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.仅雌激素受体“阳性”不足以预测乳腺癌的预后。
Breast Cancer Res Treat. 2018 Dec;172(3):627-636. doi: 10.1007/s10549-018-4948-y. Epub 2018 Sep 14.
3
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.BCT 评分可预测激素受体阳性、HER2 阴性、淋巴结阴性的亚洲乳腺癌患者的化疗获益。
PLoS One. 2018 Nov 21;13(11):e0207155. doi: 10.1371/journal.pone.0207155. eCollection 2018.
4
Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.单激素受体阳性乳腺癌的预后较差:与三阴性乳腺癌的结局相似。
BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.
5
Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.在淋巴结阴性、HER2阳性乳腺癌女性患者中,根据局部治疗类型和曲妥珠单抗使用情况的局部区域复发及生存结果
Ann Surg Oncol. 2014 Oct;21(11):3490-6. doi: 10.1245/s10434-014-3767-6. Epub 2014 May 20.
6
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.磷酸化HER2在接受辅助曲妥珠单抗治疗的HER2阳性乳腺癌患者中的预后价值。
Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.
7
Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication.采用核心针活检替代全切片免疫组化 4 评分评估乳腺癌预后。
J Clin Pathol. 2018 Dec;71(12):1084-1089. doi: 10.1136/jclinpath-2018-205228. Epub 2018 Sep 18.
8
Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.FOXA1 表达对激素受体阳性乳腺癌患者预后的影响。
Ann Surg Oncol. 2012 Apr;19(4):1145-52. doi: 10.1245/s10434-011-2094-4. Epub 2011 Oct 8.
9
Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.体重指数与激素受体或人表皮生长因子受体2的表达在乳腺癌生存方面的关系。
BMC Cancer. 2015 Nov 6;15:865. doi: 10.1186/s12885-015-1879-4.
10
Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.孕激素受体表达在雌激素受体阳性、人表皮生长因子受体2阴性、淋巴结阴性且Ki-67标记指数低的浸润性乳腺癌中的预后意义
Clin Breast Cancer. 2017 Feb;17(1):41-47. doi: 10.1016/j.clbc.2016.06.012. Epub 2016 Jun 25.

引用本文的文献

1
Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay.通过多基因检测预测激素受体阳性、人表皮生长因子受体2阴性且伴有腋窝淋巴结转移的乳腺癌新辅助化疗反应
J Breast Cancer. 2022 Dec;25(6):473-484. doi: 10.4048/jbc.2022.25.e49. Epub 2022 Nov 18.

本文引用的文献

1
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.BCT 评分可预测激素受体阳性、HER2 阴性、淋巴结阴性的亚洲乳腺癌患者的化疗获益。
PLoS One. 2018 Nov 21;13(11):e0207155. doi: 10.1371/journal.pone.0207155. eCollection 2018.
2
Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer.用于预测韩国乳腺癌患者Oncotype DX™复发评分的西方列线图的验证
J Breast Cancer. 2018 Jun;21(2):222-226. doi: 10.4048/jbc.2018.21.2.222. Epub 2018 Jun 20.
3
Clinical utility of multigene profiling assays in early-stage breast cancer.多基因检测分析在早期乳腺癌中的临床应用
Curr Oncol. 2017 Oct;24(5):e403-e422. doi: 10.3747/co.24.3595. Epub 2017 Oct 25.
4
Interlaboratory variability of Ki67 staining in breast cancer.乳腺癌中Ki67染色的实验室间变异性。
Eur J Cancer. 2017 Oct;84:219-227. doi: 10.1016/j.ejca.2017.07.041. Epub 2017 Aug 19.
5
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.一种用于预测 HR+/HER2- 早期乳腺癌患者远处转移风险的新分子预后评分。
Sci Rep. 2017 Mar 28;7:45554. doi: 10.1038/srep45554.
6
P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.P53和Ki-67作为三阴性乳腺癌患者的预后标志物
PLoS One. 2017 Feb 24;12(2):e0172324. doi: 10.1371/journal.pone.0172324. eCollection 2017.
7
A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.腔面型乳腺癌中Ki-67计数方法的比较:平均法与热点法
PLoS One. 2017 Feb 10;12(2):e0172031. doi: 10.1371/journal.pone.0172031. eCollection 2017.
8
Risk Stratification and Intrinsic Subtype Classification of Breast Cancer: a Multi-Parameter Test to Rule Them All?乳腺癌的风险分层与内在亚型分类:一种能统括一切的多参数检测方法?
J Natl Cancer Inst. 2016 Apr 29;108(9). doi: 10.1093/jnci/djw118. Print 2016 Sep.
9
Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.诺丁汉预后指数升级版(NPI+)可预测原发性乳腺癌远处转移的风险。
Breast Cancer Res Treat. 2016 May;157(1):65-75. doi: 10.1007/s10549-016-3804-1. Epub 2016 Apr 26.
10
Validity of the online PREDICT tool in older patients with breast cancer: a population-based study.在线PREDICT工具在老年乳腺癌患者中的有效性:一项基于人群的研究。
Br J Cancer. 2016 Feb 16;114(4):395-400. doi: 10.1038/bjc.2015.466. Epub 2016 Jan 19.

激素受体阳性、HER2 阴性早期乳腺癌中 BCT 评分与预后因素的临床验证。

Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer.

机构信息

Department of Surgery, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.

Department of Radiology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.

出版信息

In Vivo. 2019 Nov-Dec;33(6):2133-2139. doi: 10.21873/invivo.11714.

DOI:10.21873/invivo.11714
PMID:31662548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6899082/
Abstract

BACKGROUND/AIM: Multigene profiling assays provide strong evidence for predicting the prognosis of breast cancer. In this study, we aimed to evaluate the clinical validation of the BCT score with various prognostic factors.

MATERIALS AND METHODS

A total of 133 cases of hormone receptor-positive, cT1N0 breast cancers were analyzed. Risk stratification using the BCT score (Low, n=105; High, n=28) was analyzed with Ki67 index, p53 mutation, Immunohistochemistry 4 (IHC4) score, Nottingham Prognostic Index (NPI) and online PREDICT.

RESULTS

Ki67 index and NPI showed strong correlations with risk stratification based on BCT scores. Although the IHC4 score and online PREDICT were not associated with BCT score, there was a significant tendency of association with the online PREDICT results as the time of overall survival was increasing.

CONCLUSION

Risk classification based on BCT scores might have a clinical significance as a prognostic marker in hormone receptor-positive, HER2-negative, early breast cancer.

摘要

背景/目的:多基因分析检测为预测乳腺癌的预后提供了有力证据。本研究旨在评估 BCT 评分与各种预后因素的临床验证。

材料和方法

共分析了 133 例激素受体阳性、cT1N0 乳腺癌患者。采用 BCT 评分(低,n=105;高,n=28)进行风险分层,分析 Ki67 指数、p53 突变、免疫组织化学 4(IHC4)评分、诺丁汉预后指数(NPI)和在线 PREDICT。

结果

Ki67 指数和 NPI 与基于 BCT 评分的风险分层密切相关。尽管 IHC4 评分和在线 PREDICT 与 BCT 评分无相关性,但随着总生存时间的延长,在线 PREDICT 结果有明显的相关性趋势。

结论

基于 BCT 评分的风险分类可能作为激素受体阳性、HER2 阴性、早期乳腺癌的预后标志物具有临床意义。